Human_papillomavirus_type_16_nucleoprotein_E7_is_a_tumor_rejection_antigen._It_has_been_speculated_that_immunological_mechanisms_play_an_important_role_in_the_control_of_carcinomas_associated_with_human_papillomavirus_(HPV),_such_as_cervical_cancers._We_have_now_demonstrated_that_immunization_of_C3H/HeN_mice_by_syngeneic_nontumorigenic_fibroblast-like_cells_that_contain_the_transfected_HPV-16_E7_gene_conferred_protection_against_transplanted_cells_from_a_HPV-16_E7-positive_syngeneic_tumor._This_protection_was_HPV-16_E7-specific_and_was_mediated_by_CD8+_lymphocytes,_which_presumably_were_cytotoxic_T_lymphocytes._These_results_indicate_that_tumor_cells_containing_HPV-16_E7,_either_as_a_result_of_transfection,_as_in_our_studies,_or_naturally,_as_occurs_in_many_human_carcinomas,_can_induce_a_tumor-specific_rejection_response_and_serve_as_targets_for_such_a_response._The_system_described_here_provides_an_animal_model_to_further_study_immune_responses_to_HPV-associated_malignancies_and_to_test_the_efficacy_of_anti-HPV_vaccines_toward_the_therapy_and_prevention_of_such_tumors.